Optimistic Investors Push Bio-Thera Solutions, Ltd. (SHSE:688177) Shares Up 44% But Growth Is Lacking

The Bio-Thera Solutions, Ltd. (SHSE:688177) share price has done very well over the last month, posting an excellent gain of 44%. The bad news is that even after the stocks recovery in the last 30 days, shareholders are still underwater by about 9.9% over the last year.

Since its price has surged higher, you could be forgiven for thinking Bio-Thera Solutions is a stock to steer clear of with a price-to-sales ratios (or "P/S") of 14.8x, considering almost half the companies in China's Biotechs industry have P/S ratios below 7x. However, the P/S might be quite high for a reason and it requires further investigation to determine if it's justified.

View our latest analysis for Bio-Thera Solutions

How Has Bio-Thera Solutions Performed Recently?

Recent times have been advantageous for Bio-Thera Solutions as its revenues have been rising faster than most other companies. The P/S is probably high because investors think this strong revenue performance will continue. You'd really hope so, otherwise you're paying a pretty hefty price for no particular reason.

If you'd like to see what analysts are forecasting going forward, you should check out our free report on Bio-Thera Solutions.

Is There Enough Revenue Growth Forecasted For Bio-Thera Solutions?

The only time you'd be truly comfortable seeing a P/S as steep as Bio-Thera Solutions' is when the company's growth is on track to outshine the industry decidedly.

If we review the last year of revenue growth, the company posted a terrific increase of 47%. The latest three year period has also seen an excellent 71% overall rise in revenue, aided by its short-term performance. Therefore, it's fair to say the revenue growth recently has been superb for the company.

Looking ahead now, revenue is anticipated to climb by 51% each year during the coming three years according to the three analysts following the company. Meanwhile, the rest of the industry is forecast to expand by 533% each year, which is noticeably more attractive.

With this information, we find it concerning that Bio-Thera Solutions is trading at a P/S higher than the industry. Apparently many investors in the company are way more bullish than analysts indicate and aren't willing to let go of their stock at any price. Only the boldest would assume these prices are sustainable as this level of revenue growth is likely to weigh heavily on the share price eventually.

The Final Word

The strong share price surge has lead to Bio-Thera Solutions' P/S soaring as well. Generally, our preference is to limit the use of the price-to-sales ratio to establishing what the market thinks about the overall health of a company.

It comes as a surprise to see Bio-Thera Solutions trade at such a high P/S given the revenue forecasts look less than stellar. The weakness in the company's revenue estimate doesn't bode well for the elevated P/S, which could take a fall if the revenue sentiment doesn't improve. This places shareholders' investments at significant risk and potential investors in danger of paying an excessive premium.

You should always think about risks. Case in point, we've spotted 2 warning signs for Bio-Thera Solutions you should be aware of.

If you're unsure about the strength of Bio-Thera Solutions' business, why not explore our interactive list of stocks with solid business fundamentals for some other companies you may have missed.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.